ArticleClinical case reports2022

Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy.

Senji Hoshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.